We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BGI and Diagenode SA Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation
Product News

BGI and Diagenode SA Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation

BGI and Diagenode SA Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation
Product News

BGI and Diagenode SA Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BGI and Diagenode SA Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bioruptor NGS BGI and Diagenode SA have announced that they will enter into a close collaboration for the implementation of standard methods in epigenetics and next generation sequencing sample preparation.

Diagenode will provide BGI with early access to its new developments in chromatin or DNA methylation analysis methods and tools.

Diagenode aims to increase the consistency and precision of enrichment assays, such as ChIP, MeDIP, MBD capture, bisulfite conversion, and DNA fragmentation, prior to next generation sequencing.

"Consistency is extremely important, not only for saving reagents and precious samples, but also for creating universal high standards in the emerging field of epigenetics," said Didier Allaer, CEO of Diagenode. "We are very proud to be partnering with BGI in these domains."

"We have been successfully using Diagenode's Bioruptors® and reagents for epigenetics, and in exon sequencing, for years now and have implemented them in all of our facilities across China. We are delighted to be able to expand our collaboration with Diagenode, whose reliability and creativity for improving consistency is proven," said Jihua Sun, Lead of Epigenetics Sequencing Platform, and Renhua Wu, Lead of Exon Sequencing Platform of BGI-Shenzhen.

Advertisement